Abstract
Background: Association between endocan and nontraditional anthropometric indices, as distinct cardiovascular disease risk factors, has not been examined in previous studies. Endocan is a novel inflammation biomarker with its higher levels involved in cardiometabolic diseases development. Taking into consideration that obesity is an independent risk factor for many cardiometabolic diseases, we aimed to explore the relationship between endocan levels and novel anthropometric indices i.e., body adiposity index (BAI), cardiometabolic index (CMI), a body shape index, body roundness index, conicity index, lipid accumulation product index and visceral adiposity index and traditional ones i.e., waist circumference, hip circumference, body mass index, waist-to-height ratio and waist-to-hip ratio in adult population. Methods: A total of 177 participants were included. Anthropometric indices and biochemical parametres were measured. Results: Univariate regression analysis demonstrated positive correlations of endocan and almost all anthropometric data. To explore independent associations of endocan and anthropometric parameters, the Model which fulfilled criteria for ordinal regression testing was created. Adjusted odds for BAI given in the Model (OR=1.120, 95% CI 1.036-1.212, P=0.004), demonstrated that a rise in BAI by 1 unit increased the probability of higher endocan concentration by 12%. As well, a rise in CMI for 1 unit, increased the probability for higher endocan levels for 2.6 times (OR=2.599, 95% CI 1.006-6.712, P=0.049). A total of 20.1% of variation in endocan levels could be explained by this Model. Conclusions: Non-traditional obesity indices, BAI and CMI independently correlated with higher serum endocan levels in adult population.
Publisher
Centre for Evaluation in Education and Science (CEON/CEES)
Subject
Biochemistry (medical),Clinical Biochemistry
Reference33 articles.
1. Cimen AO, Emet S, Elitok A. Endocan: a biomarker predicting successful reperfusion after coronary artery bypass surgery of acute coronary syndrome patients. Eur Rev Med Pharmacol Sci 2019; 23: 338-42.;
2. Klisić A, Kavarić N, Stanišić V, Vujčić S, Spasojević-Kalimanovska V, Ninić A, Kotur-Stevuljević J. Endocan and a novel score for dyslipidemia, oxidative stress and inflammation (DOI score) are independently correlated with glycated hemoglobin (HbA1c) in patients with prediabetes and type 2 diabetes. Arch Med Sci 2020; 16(1): 42-50.;
3. Ekiz-Bilir B, Bilir B, Aydın M, Soysal-Atile N. Evaluation of endocan and endoglin levels in chronic kidney disease due to diabetes mellitus. Arch Med Sci 2019; 15(1): 86-91.;
4. Klisić A, Kavarić N, Abenavoli L, Stanišić V, Spasojević-Kalimanovska V, Kotur-Stevuljević J, Ninić A. Is endocan a novel potential biomarker of liver steatosis and fibrosis? J Med Biochem 2020; 39(3): 363-71.;
5. Klisić A, Kavarić N, Vujčić S, Spasojević-Kalimanovska V, Ninić A, Kotur-Stevuljević J. Endocan and advanced oxidation protein products in adult population with hypertension. Eur Rev Med Pharmacol Sci 2020; 24(12): 7131-7137. doi: 10.26355/eurrev_202006_21707;
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献